Editas medicine stock price.

Editas Medicine is a CRISPR company based out of Cambridge, Massachusetts, working "to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines " At the ...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 3.99% so far this month. During the month of August, Editas Medicine Inc’s stock price has reached a high of $9.52 and a low of $8.39. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ...Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Editas Medicine Inc stock price live 10.42, this page displays NASDAQ EDIT stock exchange data. View the EDIT premarket stock price ahead of the market session or …Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.

In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...

Jun 20, 2023 · On June 15, Editas Medicine ( EDIT 3.66%) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use ...

What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ...Over the past year, shares of gene-editing companies Editas Medicine ( EDIT -0.23%) and CRISPR Therapeutics ( CRSP 6.42%) have shot up 129% and 212%, respectively. Their mouth-watering returns ...Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock on the same terms and conditions. All of the shares in the offering ...Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Editas Medicine stock quote and company news. Get the latest EDIT company stock news & quotes.

The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119 ...

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...

The stock bounced back a bit toward the end of the day but was still down as much as 13.8% by 2 p.m. EST. Editas has a 52-week low of $9.59 and a 52-week high of $37.50, and is down more than 60% ...Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy ...Jun 15, 2023 · CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one trading days, and ...You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.

Editas Medicine stock declined 13% over a 5-day trading period ending 1/21/2021, compared to broader market (S&P500) rise of 1.3%. A change of -13% or more over 5 trading days is a 6% likelihood ...The stock option provides for the purchase of up to 123,350 shares of Editas Medicine common stock at a price of $8.00 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Ms. Deardorf’s ...The Editas Medicine, Inc stock price fell by -0.754% on the last day (Thursday, 30th Nov 2023) from $10.61 to $10.53.During the last trading day the stock fluctuated 5.51% from a day low at $10.44 to a day high of $11.01.The price has risen in 6 of the last 10 days and is up by 19.12% over the past 2 weeks. Volume has increased on …Oct 15, 2020 · The Editas Medicine stock forecast is 21.770642845038 USD for 2024 November 30, Saturday; and 92.327 USD for 2028 November 30, Thursday with technical analysis. Editas Medicine (EDIT) stock price prediction is 21.770642845038 USD. It's been a tough year for Editas Medicine (EDIT-0.26%) so far. As of the market close on Monday, the stock was down 42%. But shares of Editas were rebounding by 8.2% as of 11:25 a.m. EST on ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.

Mar 27, 2023 · Editas Medicine's cash burn of US$181m is about 36% of its US$503m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's ...

The Editas Medicine, Inc stock price fell by -0.754% on the last day (Thursday, 30th Nov 2023) from $10.61 to $10.53. During the last trading day the stock fluctuated 5.51% from a day low at $10.44 to a day high of $11.01. The price has risen in 6 of the last 10 days and is up by 19.12% over the past 2 weeks.Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis. Citigroup Upgrades Editas Medicine to Buy From Neutral, Price Target is $11 · ANALYST RECOMMENDATIONS : Dollar General, On Holding, Rio Tinto, Solaredge, Thermo ...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Different countries and cultures worldwide have used medicinal plants for thousands of years. Several studies have looked into the usefulness of these medicinal plants. However, more research is still ongoing to understand the medical benef...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksDec 1, 2023 · See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, ...

Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85. The forecasts range from a low of $7.00 to a high of $30.00. The average ...

Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...

Summary of all time highs, changes and price drops for Editas Medicine; Historical stock prices; Current Share Price: US$10.77: 52 Week High: US$11.93: 52 Week Low ...The genome editing company's revenue was $6.3 million. That's rather impressive for a clinical-stage biotech, and well up from the roughly $379,000 Editas posted in the second quarter of 2021. Net ...Editas Medicine, Inc. (EDIT) is a clinical-stage genome editing company that develops treatments for cancer and other diseases. The stock price, news, quote and history of EDIT are shown on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield, fair value and more.Aug 23, 2023 · The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119 ... All three healthcare stocks are showing solid long-term potential. ... Editas Medicine is focusing on a gene therapy EDIT-301 for rare blood disorders. ... Price as of November 30, 2023, 4:00 p.m ...CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by …Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. ... Shares of Editas Medicine (EDIT 2.28%) ...Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Editas Medicine, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: EDIT | Nasdaq ... RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating ... Stock Editas Medicine, Inc. - Nasdaq . Consensus Editas Medicine, Inc. CATEGORIES. Indexes; …The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business. Shares of Editas Medicine ( EDIT -0.26%) were down as much as 21% at one point on Thursday. The stock closed at $12.25 on Wednesday and opened at only $9.90 on Thursday, falling to as low as $9.61 ...

EDIT Editas Medicine Inc. 10.57 -0.15 ( -1.40%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.10.68 BATS BZX Real-Time Price As of 3:23pm ET +0.15 / +1.42% Today’s Change 6.08 Today ||| 52-Week Range 11.93 +20.41% Year-to-Date Quote Profile News Charts Forecasts Financials Shareholders...Nov 24, 2023 · Editas Medicine Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 10.97. Positive dynamics for Editas Medicine shares will prevail with possible volatility of 3.528%. Pessimistic target level: 10.80. Optimistic target level: 11.19. Instagram:https://instagram. vix stocktwitsverizon historical stock pricebest credit card for restaurants and barsowner builder construction loans Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. best sites for penny stock tradingkevin o'leary start engine CAMBRIDGE, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical data from the Phase 1/2 BRILLIANCE trial ... the merge nft Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 19.25% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.27. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.48. Year to date, Editas ...Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. ... The sustainability of the stock's immediate price movement ...It's been a tough year for Editas Medicine (EDIT-0.26%) so far. As of the market close on Monday, the stock was down 42%. But shares of Editas were rebounding by 8.2% as of 11:25 a.m. EST on ...